Freedom to Do More With QUADRAMET®

    • 62% to 72% of patients experienced relief1
    • Moderate, predictable, and transient myelosuppression2
    • 16-week duration of relief with a single 1.0 mCi/kg injection3
    • Acts systemically to target multiple lesion sites4

THIS SITE IS FOR US HEALTHCARE PROFESSIONALS ONLY

horse freedom to do more

Quadramet is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radonuclide bone scan More

QUADRAMET Clinical Safety Updates - JUST PUBLISHED

Phase I Study of Samarium - 153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer

-Morris MJ, et al. J Clin Oncol. May 20, 2009; Vol.27, No 15

Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

-Tu S, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ, Journal of Clinical Oncology 2009 May; JCO.2008.20.5393v1

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

-Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, et. al., Journal of Clinical Oncology 2009 May; 27:2429-2435

REFERENCES:

  1. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
  2. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.
  3. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
  4. Quadramet (samarium Sm-153 lexidronam injection) prescribing information. April 2008

Q-0301-09